NSE filing, NSE: STAR. Summary written from the filing by ALFA Finder's alert engine.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,100.90
- Market cap
- ₹10,147 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 16.5×Sector 46.1×
- Promoter holding
- 29.00%+1.09% QoQ
- FII holding
- 27.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Management Change
Strides Pharma's board appointed Biren Gabhawala as Non-Executive Independent Director effective November 1, 2026, for five years. He is a Chartered Accountant with extensive audit and listed-company board experience.
- Execution
- Five-year term effective November 1, 2026
Strides Pharma Science Employee Stock Options
Strides Pharma allotted 7,500 equity shares to an employee exercising options under the Strides ESOP 2016 Plan. Paid-up capital rises to 92,180,214 shares.
Strides Pharma Science Investor Presentation: Key Takeaways
Q2FY27 revenue ₹14,297m (+17.1% YoY), EBITDA ₹2,509m (17.6% margin), reported PAT ₹1,341m (+2.0%). Ex-US revenue surpassed US for the first time; US ~$375m FY28 aspiration pushed beyond FY28.
Strides Pharma Science Q2 FY27 Results: Net Profit ₹134.1 Cr, Up 2.0% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,430 Cr (+17.1% YoY) and net profit of ₹134.1 Cr (+2.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹134.1 Cr · +2.0% YoY
Strides Pharma Science Board Meeting Date
Strides Pharma will hold a board meeting on 29 October 2026 to consider unaudited quarterly and half-year results. Trading window stays closed from 1 October until 48 hours after results.
Strides Pharma Science Other Announcement
Strides Pharma Science Limited submitted its quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Other results update announcements
All →CARE Ratings Results Update
CARE Ratings reported strong Q2 and H1 FY27 operating income and profit growth. The board also declared an interim dividend of Rs 10 per share.
EPACK Durables Results Update
EPACK Durable reported record first-half revenue and strong Q2 FY27 growth. The board also approved exiting its EPAVO joint venture stake.
3i Infotech Results Update
3i Infotech reported Q2FY27 revenue of Rs.182.0 crore, up 4.1% year-on-year. Quarterly PAT stood at Rs.6.7 crore and 25 new client wins were added.
Suryoday Small Finance Bank Results Update
Suryoday Small Finance Bank released a press release on its unaudited Q2 and H1 FY27 results. The release highlights profit after tax of Rs.151.7 Cr for H1 FY27, up 131% year on year.
Indegene Results Update
Indegene reported Q2 FY27 revenue of ₹11,223M, up 39.5% YoY, with PAT of ₹1,123M. H1 USD revenue growth reached a four-year high of 27.0%.
Kalpataru Results Update
Kalpataru's Q2 FY27 revenue was Rs.437 Crore with a Rs.71 Crore PAT loss. Pre-sales fell 5% year-on-year, while collections stayed flat.